Senior Writer, Medicine, and Editorial Director, Events
Matthew Herper is a senior writer at STAT, where he covers medicine and oversees the editorial portion of STAT’s events. With two decades of experience, he focuses on medical innovation, pharmaceuticals, and healthcare, exploring both their promises and challenges. He has been featured in RealClearHealth, STAT News, and RamaOnHealthcare.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Matthew Herper's coverage primarily focuses on the healthcare and pharmaceutical sectors, with an emphasis on data-driven insights and industry announcements. His articles frequently cite data, incorporate press releases, and feature private sector announcements.
Given his extensive use of data in reporting, he may be particularly interested in sources who can provide statistical analysis or empirical evidence related to developments in pharmaceuticals, medical research, cancer treatment, gene editing, or drug development.
He does not appear to have a specific geographic focus but provides comprehensive coverage of global trends within the healthcare and pharmaceutical industries. When reaching out to him with pitches or expert commentary offers it should align with these thematic areas for higher chances of engagement.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Matthew Herper
‘Two drugs in one' candidate, developed in China, is a highlight at ASCO
By: Katherine MacPhail, Adam Feuerstein, Matthew Herper, Angus Chen
This is STAT's ASCO in 30 Seconds newsletter You're reading the web edition of ASCO in 30 Seconds, STAT's guide to the American Society of Clinical Oncology annual meeting.
By: Angus Chen, Katherine Macphail, Adam Feuerstein, Matthew Herper
Here is some of what you may have missed from the world's largest cancer research meeting.
Pfizer said Monday that an experimental drug it hoped could replace a widely used chemotherapy in one of the most common forms of lung cancer fell short in a clinical trial.
By: Brittany Trang, Matthew Herper
AI giant is seeking to fundamentally upend the life sciences Anthropic, the artificial intelligence firm, on Tuesday announced the availability
Researchers have created what they say may count as the first synthetic cell, and have started a public benefit corporation to share the technology with other scientists. It's a piece of science that generates as many questions as answers. They are unlike cells in nature, but have cell-like properties that are spurring a debate about whether they might even be considered alive.
By: Matthew Herper
Even if the biggest claims about the technology are hype, it may still have an immediate impact
Even if the biggest claims about the technology are hype, it may still have an immediate impactThe most convincing thing Dario Amodei, the CEO and
By: Matthew Herper, Jason Mast
How a father’s quest may shape the future of rare disease gene therapy.
By: Jason Mast, Matthew Herper
A father's $70 million pursuit of a gene therapy has implications for an entire field Highlights
